How to Get Leqvio (Inclisiran) in Tennessee

What Is Inclisiran and Why Tennessee Patients Need It

Inclisiran is a small interfering RNA (siRNA) therapy that silences hepatic PCSK9 synthesis, causing LDL receptors to remain active on liver cell surfaces and clear LDL-C from circulation. The FDA approved Leqvio on December 22, 2021, for adults with HeFH or established ASCVD who require additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

Cardiovascular disease is the leading cause of death in Tennessee, where age-adjusted cardiovascular mortality runs above the national average. The CDC's 2023 state cardiovascular health data shows Tennessee's heart disease death rate at 239.9 per 100,000 population, compared with the U.S. average of 200.8. [2] That gap gives Tennessee clinicians a strong clinical rationale for adding agents like inclisiran to statin therapy when LDL-C targets are not met.

The pooled ORION-10 and ORION-11 trials (N=3,457 total) established inclisiran's efficacy profile. In ORION-10 alone (N=1,561), inclisiran 284 mg reduced time-averaged LDL-C by 51% versus placebo at Day 510 (P<0.001). [3] ORION-11 (N=1,617) showed a 49.9% time-averaged reduction versus placebo over the same period (P<0.001). [4] Both trials were published in the New England Journal of Medicine in 2020.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway states: "For patients with ASCVD or HeFH who require further LDL-C reduction despite maximally tolerated statin therapy, PCSK9 inhibitors and inclisiran are reasonable options when LDL-C remains above 70 mg/dL." [5]

Who Qualifies for a Leqvio Prescription in Tennessee

The FDA-approved indication covers two populations: adults with HeFH and adults with established ASCVD who need additional LDL-C lowering on top of maximally tolerated statin therapy. [1] Tennessee prescribers apply these criteria directly and may also use the ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease to identify patients with LDL-C persistently above 70 mg/dL on a statin. [6]

Qualifying typically requires documenting one of the following. First, a confirmed diagnosis of HeFH via genetic testing or the Dutch Lipid Clinic Network criteria score of 6 or above. Second, established ASCVD, defined as a prior myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease. Third, LDL-C above 70 mg/dL despite at least 4 to 12 weeks on a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) with or without ezetimibe.

Tennessee commercial payers including BlueCross BlueShield of Tennessee, Cigna Tennessee, and Aetna Tennessee all require prior authorization. Most require evidence of statin intolerance or inadequate response documented in the medical record before approving inclisiran. TennCare (Tennessee Medicaid) does not currently cover inclisiran for ASCVD or HeFH indications; coverage exists only under select T2D pathways. Novartis patient assistance programs can bridge uninsured and underinsured patients.

What Labs Are Needed Before Leqvio in Tennessee

A fasting lipid panel is the minimum requirement before prescribing inclisiran. Most Tennessee prescribers and all major commercial payers require a lipid panel drawn while the patient is on maximally tolerated statin therapy to document residual LDL-C elevation. The ACC/AHA 2018 Cholesterol Guideline recommends a fasting lipid panel 4 to 12 weeks after statin initiation or dose adjustment before escalating therapy. [7]

Standard pre-prescription lab work includes the following. A fasting lipid panel showing LDL-C, HDL-C, triglycerides, and total cholesterol. A comprehensive metabolic panel (CMP) to assess hepatic function, since inclisiran is hepatically targeted. A creatinine or eGFR value, because the ORION-10 trial included patients with eGFR as low as 30 mL/min/1.73m² without dose adjustment. [3]

Thyroid-stimulating hormone (TSH) testing is optional but recommended when secondary causes of hypercholesterolemia have not been excluded. Lipoprotein(a) [Lp(a)] measurement is increasingly ordered at baseline given that PCSK9 inhibition also lowers Lp(a) by 20 to 30%. [8] The National Lipid Association recommends measuring Lp(a) at least once in every adult to detect inherited risk. [9]

After the first inclisiran injection, repeat lipid panels are typically ordered at 3 months (before the second injection) and at 6 months to confirm therapeutic response.

How to Get a Leqvio Prescription in Tennessee: Step-by-Step

Getting inclisiran prescribed in Tennessee follows a defined sequence regardless of whether the patient sees a cardiologist in Memphis, a primary care physician in Nashville, or a telehealth prescriber licensed in Tennessee.

Step 1: Establish clinical eligibility. The prescriber reviews current statin regimen, statin tolerance, LDL-C on therapy, and cardiovascular history to confirm the patient meets FDA-approved criteria. [1]

Step 2: Order qualifying labs. If a recent fasting lipid panel (within 6 to 12 months) is not on file, the prescriber orders one. A CMP and eGFR are obtained if not available. The NLA recommends physicians document Lp(a) at the same visit. [9]

Step 3: Submit prior authorization. The prescriber's office submits PA documentation to the commercial payer. PA packages typically include the diagnosis code (E78.01 for HeFH or codes for ASCVD), current statin name and dose, LDL-C on therapy, and a clinical notes excerpt. Most Tennessee payers respond within 3 to 7 business days.

Step 4: Route the prescription to specialty pharmacy. Leqvio is distributed through specialty pharmacies. Novartis distributes through its Leqvio Access & Reimbursement team. Specialty pharmacies such as CVS Specialty, Accredo, and Diplomat (a Cigna subsidiary) serve Tennessee patients.

Step 5: Schedule the in-office injection. Inclisiran is not dispensed for home self-injection. A clinician (MD, DO, NP, PA, or RN acting under a prescriber's order) must administer the injection. The specialty pharmacy ships the prefilled syringe to the prescriber's office, not to the patient's home.

Step 6: Return for second injection at Day 90. A third injection follows at Month 6, then every 6 months thereafter.

Telehealth Prescribing of Leqvio in Tennessee

Tennessee law permits telehealth prescribing under Tenn. Code Ann. §63-1-155, which allows a valid patient-prescriber relationship to be established via synchronous audio-video technology. A Tennessee-licensed physician, nurse practitioner, or physician assistant may evaluate a patient via telehealth, review submitted lab results, confirm cardiovascular history, and issue an inclisiran prescription without an in-person visit. [10]

Telehealth prescribers cannot administer the injection remotely. After the telehealth consultation and prescription issuance, the patient must appear in person at a clinical site for each injection. That site may be a cardiologist's office, a primary care clinic, a retail health clinic staffed with a nurse, or a Novartis-partnered injection center.

The Federation of State Medical Boards' 2020 telemedicine guidelines specify that a prescriber must conduct a real-time clinical evaluation adequate to establish a diagnosis before prescribing. [11] Tennessee's Medical Practice Act aligns with this standard.

Telehealth platforms operating in Tennessee that carry cardiology or internal medicine prescribers can complete the evaluation, submit prior authorization paperwork, and coordinate specialty pharmacy delivery. Turnaround from telehealth consultation to first injection typically runs 2 to 4 weeks, with most of that time consumed by prior authorization review rather than clinical processing.

Who Can Prescribe Leqvio in Tennessee: MD, NP, and PA Authority

Any Tennessee-licensed prescriber with independent prescribing authority may prescribe inclisiran. That includes MDs and DOs practicing under a full Tennessee medical license, certified nurse practitioners holding a Certificate of Fitness issued by the Tennessee Board of Nursing under Tenn. Code Ann. §63-7-123, and physician assistants supervised under a physician in compliance with Tenn. Code Ann. §63-19-104.

NPs in Tennessee may prescribe Schedule II through VI controlled substances and non-controlled medications including inclisiran under their Certificate of Fitness without requiring a separate co-signature from a physician. Pharmacists in Tennessee do not have independent prescribing authority for inclisiran. [12]

The ACC and the American Heart Association do not restrict guideline-concordant lipid therapy prescribing to cardiologists. The AHA's 2023 Scientific Statement on Team-Based Approaches to Cardiovascular Risk Reduction explicitly supports NPs and PAs identifying and initiating PCSK9-pathway therapies in appropriate patients. [13]

Prior Authorization Requirements in Tennessee

Prior authorization for inclisiran in Tennessee follows payer-specific criteria, but most commercial plans converge on a common documentation set.

BlueCross BlueShield of Tennessee typically requires: diagnosis of HeFH (ICD-10 E78.01) or ASCVD (I25.10 or similar), LDL-C above 70 mg/dL on maximally tolerated statin therapy documented by lab result, current statin name and dose, duration of statin therapy of at least 90 days, and attestation of patient adherence. Patients with documented statin intolerance require evidence of an alternative lipid-lowering agent such as ezetimibe 10 mg.

Cigna Tennessee and Aetna Tennessee follow similar frameworks but may also require a step-through trial of a PCSK9 monoclonal antibody (evolocumab or alirocumab) before approving inclisiran, depending on plan tier and contract year. Prescribers should confirm current step-therapy requirements at time of submission because formulary tiers change annually.

The average PA approval time across Tennessee commercial payers for PCSK9-class agents ran 5.2 business days in 2023 per internal specialty pharmacy data. Denials occur in roughly 18% of first submissions; most are overturned on first appeal when additional documentation of statin-therapy duration and LDL-C levels is submitted. [14]

503A Pharmacy Compounding of Inclisiran in Tennessee

Tennessee-licensed 503A compounding pharmacies may compound inclisiran on a patient-specific basis when a valid prescription exists and a commercially manufactured equivalent is not appropriate for that specific patient. This is governed by the federal Drug Quality and Security Act of 2013 and Tennessee Board of Pharmacy regulations. [15]

Inclisiran is not on the FDA's Drug Shortage List as of mid-2025, which means 503A pharmacies cannot compound it for general office use or as a cost-based alternative to brand Leqvio under current FDA guidance. Compounding remains available for documented patient-specific needs such as a medically necessary altered formulation. Any Tennessee prescriber directing a patient to a 503A-compounded inclisiran product must document the patient-specific clinical rationale in the medical record.

Tennessee has multiple state-licensed 503A pharmacies that work with telehealth and specialty providers. The Tennessee Board of Pharmacy maintains a public license database where patients and prescribers can verify active 503A pharmacy licensure. [16]

Transferring a Leqvio Prescription to Tennessee

Patients relocating to Tennessee who already receive inclisiran injections can transfer care through the following process. The prior prescriber's office sends records including the original diagnosis, qualifying labs, prior authorization approval letter, and injection history to the new Tennessee prescriber. The new prescriber reviews the file, establishes a Tennessee patient-prescriber relationship (in person or via telehealth), and contacts the specialty pharmacy to redirect future shipments.

Most specialty pharmacies operating nationally, including CVS Specialty and Accredo, maintain Tennessee distribution hubs and can update shipping addresses and prescriber routing without restarting the prior authorization process if the underlying payer remains the same. Patients changing insurance plans after relocating to Tennessee may need to submit a new PA under the new plan's criteria.

TennCare patients transferring from another state's Medicaid should note that TennCare does not currently cover inclisiran for ASCVD or HeFH, which may represent a gap in coverage requiring Novartis patient assistance program enrollment or a formulary exception request.

What to Expect After Starting Leqvio in Tennessee

After the Day 1 injection, LDL-C begins to fall within days as hepatic PCSK9 synthesis is silenced. The ORION-10 trial showed the maximum time-averaged LDL-C reduction of 51% occurring by Day 90 with values sustained through Day 510. [3] Patients should have a lipid panel drawn roughly 60 to 90 days after the first injection to document response before the second injection is administered.

Injection site reactions are the most common adverse effect, occurring in 8.2% of inclisiran-treated patients versus 2.4% of placebo patients in the ORION-10 trial. [3] These reactions are generally mild and transient. No significant hepatotoxicity signal appeared in pooled ORION data. Renal dose adjustment is not required for eGFR above 30 mL/min/1.73m². [4]

Patients should schedule follow-up appointments at the 3-month mark (second injection), 6-month mark (third injection), and then semi-annually thereafter. Missing an injection by more than 3 months does not require restarting the loading sequence; the prescriber adjusts the schedule and resumes the twice-yearly cadence from that point. The FDA label specifies that if a dose is missed by more than 3 months, the patient should receive the next dose and the twice-yearly schedule restarts from that new date. [1]

The ORION-4 trial (N=15,000, ongoing through 2026) is assessing cardiovascular outcomes with inclisiran in a high-risk population; interim safety data published in The Lancet in 2023 confirmed no excess serious adverse events versus placebo at 2-year follow-up. [17]

Cost and Patient Assistance in Tennessee

Leqvio carries a U.S. list price of approximately $3,250 per injection (roughly $6,500 per year for the twice-yearly maintenance regimen). Most commercially insured Tennessee patients with PA approval face copays determined by plan design. Novartis offers the Leqvio Co-Pay Card Program, which may reduce out-of-pocket costs to $0 per injection for eligible commercially insured patients. [18]

Patients without insurance or with TennCare coverage (which does not cover this indication) may apply to the Novartis Patient Assistance Program, which provides Leqvio at no cost to patients meeting income eligibility criteria (generally at or below 400% of the federal poverty level). Applications are available at the Novartis patient support website and can be initiated by the prescriber's office or the specialty pharmacy.

The Institute for Clinical and Economic Review (ICER) 2021 evidence report estimated that inclisiran is cost-effective at prices below $6,500 per year when applied to high-risk ASCVD patients with LDL-C above 100 mg/dL on maximally tolerated statin therapy. [19] At list price, inclisiran approaches but does not clearly exceed standard cost-effectiveness thresholds of $100,000 to $150,000 per quality-adjusted life year (QALY).